Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 25,502

Document Document Title
WO/2019/046251A1
The disclosure is directed to pharmaceutical compositions comprising of Tizanidine or a pharmaceutically acceptable salt thereof which controllably modulate the onset of at least one secondary effect associated with Tizanidine administra...  
WO/2019/044788A1
The purpose of the present invention is to provide a topical dermatological composition capable of easily improving the body's ability to balance for ordinary non-athletes who do not actively perform everyday exercise, such as housewives...  
WO/2019/044894A1
The present invention addresses the problem of providing a compound having strong conjugating activity with respect to a modified collagen, a use of the compound as a modified collagen test drug and research reagent, and a composition co...  
WO/2019/041361A1
A compound of Formula (I), pharmaceutically acceptable salts thereof, and individual enantiomers or diastereomers thereof are disclosed. Compositions and methods useful for treatment or suppression of diseases, developmental delays and s...  
WO/2019/044964A1
The present invention provides an exercise efficiency-improving composition, a fatigue-reducing composition, and a dynamic visual acuity-improving composition characterized by containing a kaempferol analog.  
WO/2019/035405A1
Provided is a nonaqueous carbon dioxide external preparation in single dosage form, the external preparation comprising a paste base, carbonate, an acid and/or a substance which produces an acid by hydrolysis, and alcohol. Merely by bein...  
WO/2019/036471A1
Disclosed are compositions comprising branched chain amino acids, urea cycle amino acids and essential amino acids for use in treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.  
WO/2019/034059A1
The present invention relates to a compound and the application thereof in treating inflammation or inflammation-related diseases, and more specifically to a compound UTLOH combination. Said compound effectively inhibits the level of LPS...  
WO/2019/036267A1
Disclosed herein are methods for increasing circulating mesenchymal stem cells by administering a compound having the general formula 1 as defined herein, or a pharmaceutically acceptable salt thereof.  
WO/2019/031425A1
The present invention mainly addresses the problem of providing a novel therapeutic agent for a motor neuron disease. Provided are: a therapeutic agent for a motor neuron disease which is characterized by comprising, as an active ingredi...  
WO/2019/031442A1
Provided is a blood flow improver which is safe and has a mild action. This blood flow improver comprises S-1-propenylcysteine or a salt thereof as an active ingredient.  
WO/2019/031495A1
The present invention addresses the problem of providing a drug which is highly stable and which contains a pyrazolone derivative such as edaravone, but does not contain sodium bisulfite. The present invention provides a drug which is de...  
WO/2019/026930A1
The present invention provides a food composition for increasing muscle mass, muscle mass increasing agent, therapeutic agent for locomotive syndrome, therapeutic agent for sarcopenia, exercise function maintenance agent, muscle atrophy-...  
WO/2019/026302A1
An agonist of 67 kDa laminin receptor, said agonist comprising as an active ingredient oolong tea polymerized polyphenols or a derivative thereof.  
WO/2019/025474A1
The present invention relates to modulators of at least one endocannabinoid system component for use in i) the prevention and/or treatment of muscular dystrophy (MD) cardiomyopathy or other cardiomyopathies, and to pharmaceutical composi...  
WO/2019/021059A1
The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hea...  
WO/2019/022216A1
The purpose of the present invention is to provide an amino acid composition having the novel, heretofore uninvestigated use of improving muscle strength with reference to a healthy state in which exhaustion does not occur. The present i...  
WO/2019/021024A1
A method of treating lower limb spasticity in a subject, particularly one which is 18 years of age or under, comprising administering to the subject an effective amount of botulinum neurotoxin. A composition for use in treating lower lim...  
WO/2019/021135A1
Composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine...  
WO/2019/022219A1
The purpose of the present invention is to provide a novel amino acid composition which can promote secretion of adrenaline and/or noradrenalin. The present invention relates to a noradrenaline secretion promoting amino acid composition ...  
WO/2019/014772A1
The present invention relates to a therapeutic antisense oligonucleotide which binds to exon 51 of the human dystrophin pre-mRNA to induce exon skipping, and conjugates and compositions thereof for the treatment of DMD.  
WO/2019/002875A8
The invention relates to improvements in drug delivery and to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (...  
WO/2019/014774A1
In one aspect, a method of preconditioning stem cells comprising exposing stem cells to low dose radiation (LDR) is provided. In another aspect, a population of preconditioned stem cells is provided, wherein the population of 5 precondit...  
WO/2019/016505A1
The present invention relates to the use of 2-chloro-2'-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof, for treating or ameliorating an autoimmune, neuromuscular disorder, e.g. the au...  
WO/2019/017338A1
Provided is a novel peptide. This peptide contains the amino acid sequence represented by SEQ ID NO: 18 and binds to an active protease, but does not bind to a precursor protease.  
WO/2019/014300A1
The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitor...  
WO/2019/014303A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2019/011167A1
The invention relates to the field of biological medicines, in particular to a bispecific recombinant protein, a nucleic acid molecule for encoding the bispecific recombinant protein, a preparation method thereof, the use of the recombin...  
WO/2019/014308A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2018/041942A9
Embodiments of the invention are directed to new polymer linked multimeric guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being...  
WO/2019/007991A1
The present disclosure relates to a MTMR2-S polypeptide, or a nucleic acid sequence producing or encoding said MTMR2-S polypeptide, for a use in the treatment of a disease or disorder associated with MTM1 mutation or deficiency. The pres...  
WO/2019/006690A1
Provided are a polypeptide pharmaceutically acceptable salt and a pharmaceutical composition thereof, said polypeptide containing an amino acid sequence YEKLLDTEI or functional variants thereof.  
WO/2018/204617A8
The present invention relates generally to stable liquid formulations comprising polypeptides with 10Fn3 domains which bind to myostatin and unit dosage forms thereof for administration various routes, including subcutaneous (SC), for tr...  
WO/2019/005685A1
A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II: wherein each o...  
WO/2019/003104A1
The disclosure relates to novel uses and methods for preventing and/or treating urinary incontinence, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an A...  
WO/2019/002875A1
The invention relates to improvements in drug delivery and to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (...  
WO/2018/236698A1
A pharmaceutically acceptable transdermal composition for the treatment of patients with musculoskeletal connective tissue fibrosis or a disorder including Dupuytren's Contracture, Peyronie's disease, Ledderhose disease, or Knuckle Pads,...  
WO/2018/234284A1
The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2018/232735A1
Provided is use of regulator in preparation of a medicament for regulating at least one of the following, wherein the regulator is used for activating or inhibiting Piezo: blood vessel development; blood pressure regulation; red blood ce...  
WO/2018/236186A1
The present invention relates to a pharmaceutical composition containing a sesquiterpene derivative or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of muscle diseases.  
WO/2018/235899A1
Provided is a method for culturing muscle stem cells while maintaining the undifferentiated properties of the cells. More specifically, muscle stem cells can be cultured while maintaining the undifferentiated properties of the cells by c...  
WO/2018/230535A1
The present invention provides a skeletal muscle injury repair accelerator which contains, as an active ingredient: at least one selected from among (1) a peptide having the amino acid sequence represented by SEQ ID NO: 1, (2) a peptide ...  
WO/2018/229629A1
A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne ...  
WO/2018/225673A1
Disclosed are: a method for manufacturing a therapeutic composition containing mammalian cells, said method comprising dispersing the mammalian cells in an aqueous glucose solution having a concentration of about 3-10% or Ringer's acetat...  
WO/2018/224636A1
The present invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle wasting occurs. The invention provides the use of inhibitors of glutamine dehydrogenase for the regenerati...  
WO/2018/225065A1
Novel aminoglycosides, represented by Formulae (e.g., a compound of Formula A, B, I, I*, III or III*, including compounds represented by Formula Ia, I**, I*a, I*b, IIIa, III**, III*a and, III*b), as defined in the instant specification, ...  
WO/2018/221521A1
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives o...  
WO/2018/221543A1
The present invention provides: an I-type crystal of (E)-2-(7-trifluoromethyl chromane-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaph thalene-1-yl)acetamide having an excellent TRPV1 antagonistic activity; a medication and a medicat...  
WO/2018/221679A1
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.  
WO/2018/221526A1
[Problem] To provide a high-calorie nutritional composition having good flavor and stable physical properties. [Solution] A nutritional composition comprises a protein source. The protein source of the nutritional composition includes wh...  

Matches 151 - 200 out of 25,502